- Home
- KNF vs BPMC Comparison
KNF vs BPMC Comparison
Compare KNF & BPMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNF
- BPMC
- Stock Information
- Founded
- KNF 1917
- BPMC 2008
- Country
- KNF United States
- BPMC United States
- Employees
- KNF N/A
- BPMC N/A
- Industry
- KNF
- BPMC Biotechnology: Pharmaceutical Preparations
- Sector
- KNF
- BPMC Health Care
- Exchange
- KNF Nasdaq
- BPMC Nasdaq
- Market Cap
- KNF 5.3B
- BPMC 5.8B
- IPO Year
- KNF N/A
- BPMC 2015
- Fundamental
- Price
- KNF $77.59
- BPMC $128.20
- Analyst Decision
- KNF Strong Buy
- BPMC Buy
- Analyst Count
- KNF 6
- BPMC 20
- Target Price
- KNF $117.17
- BPMC $127.82
- AVG Volume (30 Days)
- KNF 551.0K
- BPMC 6.4M
- Earning Date
- KNF 08-05-2025
- BPMC 07-31-2025
- Dividend Yield
- KNF N/A
- BPMC N/A
- EPS Growth
- KNF 1.95
- BPMC N/A
- EPS
- KNF 3.18
- BPMC N/A
- Revenue
- KNF $2,922,886,000.00
- BPMC $562,121,000.00
- Revenue This Year
- KNF $15.00
- BPMC $44.46
- Revenue Next Year
- KNF $7.17
- BPMC $32.78
- P/E Ratio
- KNF $24.86
- BPMC N/A
- Revenue Growth
- KNF 2.48
- BPMC 99.19
- 52 Week Low
- KNF $66.51
- BPMC $73.04
- 52 Week High
- KNF $108.83
- BPMC $128.34
- Technical
- Relative Strength Index (RSI)
- KNF 28.34
- BPMC 75.62
- Support Level
- KNF $79.40
- BPMC $127.86
- Resistance Level
- KNF $84.99
- BPMC $128.33
- Average True Range (ATR)
- KNF 3.32
- BPMC 0.41
- MACD
- KNF -1.54
- BPMC -0.32
- Stochastic Oscillator
- KNF 3.51
- BPMC 84.62
About KNF Knife Riv Holding Co.
Knife River Holding Co is an aggregates-led construction materials and contracting services provider. Its segments include Pacific, Northwest, Mountain, North Central, South, and Energy Services. Each geographic segment offers a vertically integrated suite of products and services, including aggregates, ready-mix concrete, asphalt, and contracting services, while the Energy Services segment, which has locations throughout the company's geographic footprint, produces and supplies liquid asphalt and related services, for use in asphalt road construction, and is a supplier to some of the other segments.
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.